Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes.

Carlsson A, Forsander G, Ludvigsson J, Larsen S, Ortqvist E; Swedish PREDICTIVE-Youth Study Group.

Pediatr Diabetes. 2013 Aug;14(5):358-65. doi: 10.1111/pedi.12019. Epub 2013 Mar 1.

PMID:
23448369
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.

Sreenan S, Virkamäki A, Zhang K, Hansen JB; PREDICTIVE study group.

Int J Clin Pract. 2008 Dec;62(12):1971-80. doi: 10.1111/j.1742-1241.2008.01939.x. Erratum in: Int J Clin Pract. 2009 Jan;63(1):176-7:178-80.

PMID:
19166444
[PubMed - indexed for MEDLINE]
3.

Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.

Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.

Pediatr Diabetes. 2013 May;14(3):196-202. doi: 10.1111/pedi.12012. Epub 2013 Jan 4.

PMID:
23289822
[PubMed - indexed for MEDLINE]
4.

Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.

Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.

Pediatr Diabetes. 2011 Nov;12(7):632-41. doi: 10.1111/j.1399-5448.2010.00750.x. Epub 2011 Mar 21.

PMID:
21418455
[PubMed - indexed for MEDLINE]
5.

Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.

Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S; PREDICTIVE Turkey Study Group.

Pediatr Diabetes. 2009 Sep;10(6):401-7. doi: 10.1111/j.1399-5448.2008.00497.x. Epub 2009 Feb 11.

PMID:
19220776
[PubMed - indexed for MEDLINE]
7.

Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Soewondo P, Mohamed M, Jain AB, Sy RA, Khoo CM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S10-6. doi: 10.1016/S0168-8227(13)70004-4.

PMID:
23647712
[PubMed - indexed for MEDLINE]
8.

Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.

Braun D, Konrad D, Lang-Muritano M, Schoenle E.

Pediatr Diabetes. 2008 Aug;9(4 Pt 2):382-7. doi: 10.1111/j.1399-5448.2008.00371.x. Epub 2008 Mar 5.

PMID:
18331413
[PubMed - indexed for MEDLINE]
9.

Usefulness of insulin detemir in Japanese children with type 1 diabetes.

Jinno K, Urakami T, Horikawa R, Kawamura T, Kikuchi N, Kikuchi T, Kizu R, Kosaka K, Mizuno H, Mochizuki T, Nishii A, Ohki Y, Soneda S, Sugihara S, Tatematsu T, Amemiya S; Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes.

Pediatr Int. 2012 Dec;54(6):773-9. doi: 10.1111/j.1442-200X.2012.03687.x. Epub 2012 Sep 17.

PMID:
22726205
[PubMed - indexed for MEDLINE]
10.

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

Diabetes Care. 2004 May;27(5):1081-7.

PMID:
15111525
[PubMed - indexed for MEDLINE]
11.

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, King A, Mersebach H, Davies M.

Diabetes Care. 2012 Nov;35(11):2174-81. doi: 10.2337/dc11-2503. Epub 2012 Aug 28.

PMID:
22933438
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.

Meneghini LF, Dornhorst A, Sreenan S; PREDICTIVE Study Group.

Curr Med Res Opin. 2009 Apr;25(4):1029-35. doi: 10.1185/03007990902840871 .

PMID:
19281426
[PubMed - indexed for MEDLINE]
13.

[Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].

Liebl A, Wilhelm B, Kaiser M.

MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:102-9. German.

PMID:
23326928
[PubMed - indexed for MEDLINE]
14.

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.

Standl E, Lang H, Roberts A.

Diabetes Technol Ther. 2004 Oct;6(5):579-88.

PMID:
15628811
[PubMed - indexed for MEDLINE]
15.

Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.

Hermansen K, Dornhorst A, Sreenan S.

Curr Med Res Opin. 2009 Nov;25(11):2601-8. doi: 10.1185/03007990903262885.

PMID:
19739940
[PubMed - indexed for MEDLINE]
16.

Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.

Yenigun M, Honka M.

Int J Clin Pract. 2009 Mar;63(3):425-32. doi: 10.1111/j.1742-1241.2008.01973.x.

PMID:
19222627
[PubMed - indexed for MEDLINE]
17.

Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice.

Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL; SOLVE Study Group.

Endocr Pract. 2013 May-Jun;19(3):462-70. doi: 10.4158/EP12269.OR.

PMID:
23337147
[PubMed - indexed for MEDLINE]
18.

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.

Vasc Health Risk Manag. 2009;5(1):121-8. Epub 2009 Apr 8.

PMID:
19436668
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.

Hollander P, Cooper J, Bregnhøj J, Pedersen CB.

Clin Ther. 2008 Nov;30(11):1976-87. doi: 10.1016/j.clinthera.2008.11.001.

PMID:
19108786
[PubMed - indexed for MEDLINE]
20.

Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.

Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F.

Expert Opin Pharmacother. 2011 Nov;12(16):2449-55. doi: 10.1517/14656566.2011.626766. Erratum in: Expert Opin Pharmacother. 2011 Dec;12(17):2765.

PMID:
21988213
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk